The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> February 19, 2014

Interview with the CEO: Urologix, Inc. (ULGX)

Fluet, Gregory J.
Gregory J. Fluet, 44, has served as a director and as Chief Executive Officer of Urologix, Inc., since January 25, 2013. From November 30, 2012 to January 25, 2013, Mr. Fluet served as interim Chief Executive Officer. Prior to that time, he served as Executive Vice President and Chief Operating Officer, since July 14, 2008. Mr. Fluet initially joined Urologix as a consultant in February 2008 to provide strategic analysis and tactical support. Prior to joining Urologix, Mr. Fluet was an associate at Sapient Capital Management, LLC, a venture capital firm focused on early-stage investing in the health care industry, primarily minimally invasive therapeutic medical devices. While at Sapient Capital, he worked with portfolio companies that raised multiple rounds of private financing, completed initial public offerings and were acquired. He was also actively involved in all aspects of early stage medical device company development, including being a board observer, product development, intellectual property development, regulatory analysis, financial modeling, milestone-based budgeting, clinical research and strategic market assessment for portfolio companies or potential investments. Mr. Fluet graduated from Stanford University with a Bachelor of Science in mechanical engineering. Profile
TWST: You moved from the Chief Operating Officer at Urologix to its CEO in 2013. I want to ask you about this transition and also, if you could comment, about what brought you to the
Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc
CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
AI Opportunities Expand to Industrial, Utilities and Energy Sectors
India Fund Manager Expects Discretionary Spending to Grow
Inefficiency in Ex-US Markets Creates Opportunity to Buy at a Discount
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy